{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:58:49Z","timestamp":1774313929849,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.jinf.2021.11.005","type":"journal-article","created":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T23:53:46Z","timestamp":1636847626000},"page":"31-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Immunocompromised children and young people are at no increased risk of severe COVID-19"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2996-8579","authenticated-orcid":false,"given":"H.","family":"Chappell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7257-1716","authenticated-orcid":false,"given":"R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Driessens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1009-0823","authenticated-orcid":false,"given":"A.W.","family":"Tarr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.L.","family":"Irving","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8326-093X","authenticated-orcid":false,"given":"P.J.","family":"Tighe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6941-6157","authenticated-orcid":false,"given":"H.J.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5139-8667","authenticated-orcid":false,"given":"T.","family":"Harvey-Cowlishaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5011-0476","authenticated-orcid":false,"given":"L.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Shaunak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7539-9069","authenticated-orcid":false,"given":"D.","family":"Gbesemete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Leahy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.S.","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3410-7642","authenticated-orcid":false,"given":"S.N.","family":"Faust","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"de Graaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jinf.2021.11.005_bib0001","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jama.2020.4344","article-title":"Coronavirus disease 2019 (COVID-19) in Italy","volume":"323","author":"Livingston","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jinf.2021.11.005_bib0002","doi-asserted-by":"crossref","first-page":"422","DOI":"10.15585\/mmwr.mm6914e4","article-title":"Coronavirus disease 2019 in children - United States, February 12-April 2, 2020","volume":"69","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jinf.2021.11.005_bib0003","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72\u00a0314 cases from the Chinese center for disease control and prevention","volume":"323","author":"Wu","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jinf.2021.11.005_bib0004","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S1473-3099(20)30371-6","article-title":"Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study","volume":"20","author":"de Lusignan","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jinf.2021.11.005_bib0005","doi-asserted-by":"crossref","first-page":"m3249","DOI":"10.1136\/bmj.m3249","article-title":"Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study","volume":"370","author":"Swann","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.jinf.2021.11.005_bib0006","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1136\/archdischild-2020-319363","article-title":"Prioritising paediatric surveillance during the COVID-19 pandemic","volume":"105","author":"Ladhani","year":"2020","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jinf.2021.11.005_bib0007","series-title":"SARS-CoV2 Susceptibility and Transmission Risk in Children: an Overview of Current Evidence from Public Health England\u2019s Surveillance Work","author":"Public Health England","year":"2020"},{"key":"10.1016\/j.jinf.2021.11.005_bib0008","doi-asserted-by":"crossref","first-page":"e01207","DOI":"10.1128\/mSphere.01207-20","article-title":"Seroprevalence of SARS-CoV-2 antibodies in children and adults in St. Louis, Missouri, USA","volume":"6","author":"Smith","year":"2021","journal-title":"mSphere"},{"key":"10.1016\/j.jinf.2021.11.005_bib0009","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(21)00238-5","article-title":"Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study","volume":"397","author":"He","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jinf.2021.11.005_bib0010","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0140-6736(20)31304-0","article-title":"Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study","volume":"396","author":"Stringhini","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jinf.2021.11.005_bib0011","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S1473-3099(21)00054-2","article-title":"Seroprevalence of anti-SARS-CoV-2 antibodies after the second pandemic peak","volume":"21","author":"Stringhini","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jinf.2021.11.005_bib0012","series-title":"National COVID-19 Surveillance Report","year":"2020"},{"key":"10.1016\/j.jinf.2021.11.005_bib0013","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1001\/jamapediatrics.2020.5052","article-title":"Assessment of 135\u00a0794 pediatric patients tested for severe acute respiratory syndrome coronavirus 2 across the United States","volume":"175","author":"Bailey","year":"2021","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.jinf.2021.11.005_bib0014","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2352-4642(20)30177-2","article-title":"COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study","volume":"4","author":"G\u00f6tzinger","year":"2020","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.jinf.2021.11.005_bib0015","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/S2352-4642(21)00066-3","article-title":"Children and young people remain at low risk of COVID-19 mortality","volume":"5","author":"Bhopal","year":"2021","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.jinf.2021.11.005_bib0016","series-title":"COVID-19 Rapid Guideline: Children and Young People who are Immunocompromise","year":"2020"},{"key":"10.1016\/j.jinf.2021.11.005_bib0017","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.pcl.2021.05.007","article-title":"Impact of COVID-19 on pediatric immunocompromised patients","volume":"68","author":"Connelly","year":"2021","journal-title":"Pediatr Clin North Am"},{"key":"10.1016\/j.jinf.2021.11.005_bib0018","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-044899","article-title":"COVID-19 symptom surveillance in immunocompromised children and young people in the UK: a prospective observational cohort study","volume":"11","author":"Shaunak","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.jinf.2021.11.005_bib0019","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ijid.2020.11.163","article-title":"Severe COVID-19 infection and pediatric comorbidities: a systematic review and meta-analysis","volume":"103","author":"Tsankov","year":"2021","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jinf.2021.11.005_bib0020","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.11182","article-title":"Underlying Medical conditions associated with severe COVID-19 illness among children","volume":"4","author":"Kompaniyets","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"Supplement 1","key":"10.1016\/j.jinf.2021.11.005_bib0021","first-page":"93","article-title":"SeroCovid19: prospective seroprevalence monitoring reveals substantially reduced SARS-CoV-2 infection rate among tertiary pediatric patients. Presented at BVK-SBP 49th annual congress of the Belgian Society of Pediatrics","volume":"23","author":"Hoste","year":"2021","journal-title":"Belg J Paediatr"},{"key":"10.1016\/j.jinf.2021.11.005_bib0022","article-title":"Clinical course and seroprevalence of COVID-19 in children with rheumatic diseases. Cross-sectional study from a reference centre in Spain","author":"Clara","year":"2021","journal-title":"Res Sq"},{"key":"10.1016\/j.jinf.2021.11.005_bib0023","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/gutjnl-2021-324388","article-title":"Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab","volume":"70","author":"Kennedy","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.jinf.2021.11.005_bib0024","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12882-021-02325-x","article-title":"Detection of SARS-CoV-2 antibodies in pediatric kidney transplant patients","volume":"22","author":"Alshami","year":"2021","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.jinf.2021.11.005_bib0025","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/jpids\/piaa123","article-title":"Immunocompromised seroprevalence and course of illness of SARS-CoV-2 in one pediatric quaternary care center","volume":"10","author":"Freeman","year":"2021","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.jinf.2021.11.005_bib0026","series-title":"What\u2019s the STORY?","year":"2021"},{"key":"10.1016\/j.jinf.2021.11.005_bib0027","series-title":"COVID-19: Paediatric Surveillance. 7. Serosurveys in Children","year":"2021"},{"key":"10.1016\/j.jinf.2021.11.005_bib0028","series-title":"The Green Book of Immunisation, Chapter 19 Influenza","year":"2020"},{"key":"10.1016\/j.jinf.2021.11.005_bib0029","series-title":"Clinical Characterisation Protocol (CCP)","year":"2021"},{"key":"10.1016\/j.jinf.2021.11.005_bib0030","series-title":"Everyone in the United Kingdom with Symptoms Now Eligible for Coronavirus Tests","year":"2021"},{"key":"10.1016\/j.jinf.2021.11.005_bib0031","series-title":"Government Launches NHS Test and Trace Service","year":"2020"},{"key":"10.1016\/j.jinf.2021.11.005_bib0032","series-title":"Potent Anti-SARS-CoV-2 Antibody Responses are Associated with Better Prognosis in Hospital Inpatient COVID-19 Disease","author":"Tighe","year":"2020"},{"key":"10.1016\/j.jinf.2021.11.005_bib0033","series-title":"Coronavirus (COVID-19) Infection Survey, UK: 18 December 2020","year":"2020"},{"key":"10.1016\/j.jinf.2021.11.005_bib0034","series-title":"Coronavirus (COVID-19) Infection Survey, UK: 22 January 2021","year":"2021"},{"key":"10.1016\/j.jinf.2021.11.005_bib0035","series-title":"Weekly National INFLUENZA and COVID-19 Surveillance Report","year":"2021"},{"key":"10.1016\/j.jinf.2021.11.005_bib0036","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.jaci.2020.12.620","article-title":"COVID-19 in patients with primary and secondary immunodeficiency: the United Kingdom experience","volume":"147","author":"Shields","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jinf.2021.11.005_bib0037","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1016\/j.jaip.2021.04.017","article-title":"Clinical outcome, incidence, and SARS-CoV-2 infection-fatality rates in Italian patients with inborn errors of immunity","volume":"9","author":"Milito","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jinf.2021.11.005_bib0038","series-title":"Coronavirus (COVID-19) Infection Survey: Characteristics of People Testing Positive for COVID-19 in England","year":"2021"},{"key":"10.1016\/j.jinf.2021.11.005_bib0039","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1136\/archdischild-2020-320558","article-title":"Seroprevalence of SARS-CoV-2 antibodies in children: a prospective multicentre cohort study","volume":"106","author":"Waterfield","year":"2021","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jinf.2021.11.005_bib0040","doi-asserted-by":"crossref","first-page":"3774","DOI":"10.1038\/s41467-020-17703-6","article-title":"Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion","volume":"11","author":"Simon","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jinf.2021.11.005_bib0041","article-title":"Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study","author":"Twohig","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jinf.2021.11.005_bib0042","series-title":"Illness Characteristics of COVID-19 in Children Infected with the SARS-CoV-2 Delta Variant","author":"Molteni","year":"2021"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016344532100548X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016344532100548X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T21:33:38Z","timestamp":1759008818000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016344532100548X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S016344532100548X"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2021.11.005","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunocompromised children and young people are at no increased risk of severe COVID-19","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2021.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The British Infection Association. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}